Consolidated Statement Of Cash Flows

Astellas Pharma Inc. - Filing #7332273

Concept 2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
As at
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
As at
2022-03-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss)
JPY
17,045,000,000 JPY
JPY
JPY
JPY
JPY
JPY
JPY
JPY
17,045,000,000 JPY
17,045,000,000 JPY
JPY
JPY
JPY
JPY
98,714,000,000 JPY
JPY
JPY
JPY
JPY
JPY
JPY
JPY
98,714,000,000 JPY
98,714,000,000 JPY
JPY
Impairment losses (reversal of impairment losses)
78,931,000,000 JPY
84,499,000,000 JPY
Decrease (increase) in inventories
-60,036,000,000 JPY
-7,086,000,000 JPY
Other
34,816,000,000 JPY
98,189,000,000 JPY
Subtotal
210,587,000,000 JPY
397,246,000,000 JPY
Income taxes paid
-38,112,000,000 JPY
-69,479,000,000 JPY
Net cash provided by (used in) operating activities
172,475,000,000 JPY
327,767,000,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-38,056,000,000 JPY
-36,441,000,000 JPY
Purchase of intangible assets
-44,441,000,000 JPY
-52,100,000,000 JPY
Payments for acquisition of subsidiaries
-784,974,000,000 JPY
JPY
Other
1,816,000,000 JPY
-13,353,000,000 JPY
Net cash provided by (used in) investing activities
-845,802,000,000 JPY
-84,500,000,000 JPY
Cash flows from financing activities
Purchase of treasury shares
-10,735,000,000 JPY
-60,556,000,000 JPY
Other
-16,539,000,000 JPY
-3,218,000,000 JPY
Net cash provided by (used in) financing activities
614,060,000,000 JPY
-195,623,000,000 JPY
Cash and cash equivalents
335,687,000,000 JPY
376,840,000,000 JPY
315,986,000,000 JPY
Effect of exchange rate changes on cash and cash equivalents
18,113,000,000 JPY
13,210,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.